DNA Genome In-Vitro Protein 
Drug Discovery World
AUGUST 21, 2024
With these therapies, genes can be delivered into cells to replace defective alleles or produce new functional proteins to treat or cure disease. Integrating vectors such as lentivirus stably insert their payload into the host cell genome, which is advantageous for long-term treatment. to 10% in hepatocytes. to 10% in hepatocytes.
Pharmaceutical Technology
FEBRUARY 23, 2023
Within the emerging innovation stage, DNA chips, tissue culturing automation, and mass spectrometry analysis are disruptive technologies that are in the early stages of application and should be tracked closely. However, not all innovations are equal nor do they follow a constant upward trend.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bioengineer
JANUARY 16, 2024
This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms. In the same study, those with T790M loss had a shorter treatment duration (6.1 months vs. 15.2
Drug Discovery World
MARCH 26, 2024
More importantly, it also highlighted that significant challenges remain in selecting the right therapies for the right patients despite the progress made through genomic testing and implementation of circulating tumour (ct) DNA analyses. We were there to present the latest findings from our research.
Drug Discovery World
APRIL 8, 2024
Aviv Regev, Head and Executive Vice President of Research and Early Development at Genentech, opened the session with a discussion of how advances in genomic sequencing are fostering the development of data-rich cell atlases and what that data could mean for new insights into cancer biology and novel therapeutics.
Drug Discovery World
DECEMBER 13, 2022
The genetic anomaly blocks the chemical glycosylation of a biologically important protein. Using an experimental technique called exon skipping by antisense oligonucleotides, the team corrected a mistake in the FKTN gene that blocks the chemical glycosylation of a biologically important protein. . Modifying RNA function.
XTalks
MAY 12, 2022
This diagnostic assay works on the principle of in vitro nucleic acid amplification using real-time transcription-mediated amplification (TMA) technology. The Aptima CMV Quant Assay helps to detect changes in the viral load of the transplant patient to understand the response of the individual to anti-CMV treatment.
Expert insights. Personalized for you.
59 
Let's personalize your content